Moderna files coronavirus vaccine for kids aged 6-11 in EU
Moderna has on Tuesday filed to expand the conditional licence for its COVID-19 vaccine in Europe to include children aged six to 11 years old, the company said in a statement.
The U.S. biotech said it had submitted the dossier for a two-dose course of its mRNA vaccine for children to the European Medicines Agency. The dosing of 50 micrograms per shot is half that given to adults.
“This marks our first submission for the use of our vaccine in this age group,” said Stéphane Bancel, Moderna’s chief executive officer.
Moderna last month reported the vaccine induced a strong antibody response in kids ages six to 11 — similar to that seen in young adults. The filing comes shortly after the company’s booster jab was also authorized for use in the EU, on October 25.
The biotech said study of the vaccine in children as young as six months is ongoing.
This article is part of POLITICO’s premium policy service: Pro Health Care. From drug pricing, EMA, vaccines, pharma and more, our specialized journalists keep you on top of the topics driving the health care policy agenda. Email [email protected] for a complimentary trial.